Drug Profile

Arketamine - Atai Beckley

Alternative Names: (R)-Ketamine - Atai Beckley; PCN-101

Latest Information Update: 11 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Perception Neuroscience
Developer Atai Beckley; Perception Neuroscience
Class Analgesics; Antidepressants; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanones; General anaesthetics; Small molecules
Mechanism of Action Glutamate receptor modulators; NMDA receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Depressive disorders

Most Recent Events

05 Nov 2025 ATAI Life Sciences has merged with Beckley Psytech to form Atai Beckley
26 Sep 2025 No development reported - Phase-I for Depressive disorders (In volunteers) (SC)
24 Apr 2025 Otsuka Pharmaceutical terminates license for Arketamine

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com